TICKERNERD
Menu
HALOHALOHealthcare · Biotechnology

HALO Stock Forecast: Halozyme Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$110
+1.30% on the day

The 9 Wall Street analysts covering Halozyme Therapeutics, Inc. hold a median 12-month price target of $105 — -4.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 5 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$12.5B
Ticker Nerd rank
97 / 100
Median analyst target
$105
Analysts covering
9
Revenue$481.0M+47.7% y/y
Operating income$287.7M
Net income$229.9M
Free cash flow$236.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.6%
1M
−0.4%
YTD
+63.0%
1Y
+63.8%
From 52W high
−4.8%
From 52W low
+78.0%
$62
$115
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HALO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Halozyme Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Oct 2026
97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Quality
99
Volatility
96
Revisions
92
Momentum
85
Growth
68
Accruals
66
Issuance
45
Size
14

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (45): The company has been issuing shares or taking on financing, diluting existing holders.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HALO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HALO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$70$80$90$100$110$120Jan 26Apr 26Jul 26Oct 26HALOHigh $115Median $105Low $70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
7 Buy2 Hold0 Sell
Low $70Median $105High $115

The green dot is the last close — the median target sits −4.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
2 Sept 2026HC Wainwright & Co.ReiteratesBuy$115
8 Aug 2026Leerink PartnersUpgradeOutperform—
7 Aug 2026CitizensMaintainsMarket Outperform—
7 Aug 2026CitizensMaintainsMarket Outperform$92 → $93
7 Aug 2026HC Wainwright & Co.MaintainsBuy—
7 Aug 2026HC Wainwright & Co.MaintainsBuy$95 → $115
7 Aug 2026Leerink PartnersUpgradeOutperform$83 → $110
7 Aug 2026TD CowenMaintainsBuy—
7 Aug 2026TD CowenMaintainsBuy$96 → $105
7 Aug 2026Wells FargoMaintainsEqual-Weight—
7 Aug 2026Wells FargoMaintainsEqual-Weight$75 → $95
21 July 2026HC Wainwright & Co.ReiteratesBuy$95
21 July 2026HC Wainwright & Co.ReiteratesBuy—
12 May 2026Morgan StanleyMaintainsOverweight—
12 May 2026Morgan StanleyMaintainsOverweight$96 → $93
29 Apr 2026HC Wainwright & Co.MaintainsBuy—
19 Feb 2026BenchmarkMaintainsBuy—
19 Feb 2026Wells FargoMaintainsEqual-Weight—
8 Jan 2026TD CowenMaintainsBuy—
19 Dec 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HALO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HALO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Halozyme Therapeutics, Inc. returned +63.8% against +16.6% for the S&P 500, dividends included.

HALO vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26HALOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HALO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.1%
Analysts raising
2
Analysts cutting
1
Fundamentals

Halozyme Therapeutics, Inc. (HALO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
32.1×

Cheaper than 24% of US stocks

Price / sales
7.5×

Cheaper than 18% of US stocks

Price / book
87.3×

Cheaper than 2% of US stocks

EV / EBITDA
13.7×

Cheaper than 26% of US stocks

Growth & margins
Revenue growth (YoY)
47.7%

Higher than 85% of US stocks

Earnings growth (YoY)
39.2%

Higher than 71% of US stocks

Gross margin
83.5%

Higher than 93% of US stocks

Operating margin
59.8%

Higher than 98% of US stocks

Net margin
24.9%

Higher than 86% of US stocks

Returns & dividend
Return on equity
173.7%

Higher than 98% of US stocks

Return on assets
25.5%

Higher than 99% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Halozyme Therapeutics, Inc. (HALO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Halozyme Therapeutics, Inc. has a market value of $12.5B and an enterprise value of $14.4B.

  • Revenue in the twelve months to 30 June 2026: $1.7B. The latest quarter grew 47.7% year on year.

  • Net income over the same four quarters: $413.6M, a 24.9% net margin.

  • Diluted earnings per share, trailing twelve months: $3.35.

  • Free cash flow in the twelve months to 30 June 2026: $518.5M.

  • Shares outstanding: 114.0M.

  • Trailing P/E: 32.1×; forward P/E: 10.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Halozyme Therapeutics, Inc. employs 423 people — $3.9M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

HALO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HALOHalozyme Therapeutics, Inc.$12.5B
97
BBIOBridgeBio Pharma, Inc.$12.8B
65
CORTCorcept Therapeutics, Inc.$13.1B
79
MDGLMadrigal Pharmaceuticals, Inc.$11.3B
68
TECHBio-Techne Corp.$11.3B
94
TWSTTwist Bioscience Corp.$13.5B
63
BMRNBioMarin Pharmaceutical, Inc.$11.1B
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Halozyme Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HALO news & analysis

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

PRNewsWire · 6 Oct 2026positive

Halozyme expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE® with two additional exclusive targets. The expansion increases argenx’s exclusive access to ENHANZE® from six targets to eight.

Why it matters — The expanded agreement adds two targets to Halozyme’s ENHANZE® collaboration with argenx, building on the development of VYVGART Hytrulo.

Halozyme Announces Appointment of Jim Daly to its Board of Directors

PRNewsWire · 30 Sept 2026neutral

Halozyme Therapeutics announced the appointment of James "Jim" Daly to its Board of Directors. The announcement was made on September 30, 2026, via press release from the company's headquarters in San Diego.

Why it matters — A new board member could bring fresh perspective and experience to the company's governance, which HALO watchers may consider when assessing the company's strategic direction.

Why Women-Run Companies Deserve a Place in Your Portfolio

Zacks Investment Research · 24 Sept 2026positive

Zacks Investment Research published an item highlighting women-led companies, citing HALO among stocks including BMY, TGT, NEO and ROST as examples of how women-run companies are redefining growth with discipline, agility and results, and arguing they deserve a place in investors' portfolios.

Why it matters — The piece presents HALO in a favorable light by featuring it among women-led companies praised for strong discipline, agility, and results, offering positive visibility to HALO watchers.

Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns

Zacks Investment Research · 23 Sept 2026positive

Zacks Investment Research highlighted HALO as one of four stocks that fit a Growth at a Reasonable Price (GARP) strategy, which targets stocks with solid growth prospects trading at a discount. FTNT, ABBNY, EAT and HALO were named as examples of such stocks.

Why it matters — HALO watchers would care because the company has been singled out by a research firm as a stock with solid prospects trading at a discount under the GARP approach.

Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

Zacks Investment Research · 23 Sept 2026positive

Halozyme Therapeutics (HALO) was a notable mover in the last session on higher-than-average trading volume, with its stock jumping 3.3%. The latest trend in earnings estimate revisions may help the stock continue moving higher in the near term.

Why it matters — A HALO watcher would care because the recent earnings estimate revision trend and high trading volume could signal continued upward momentum for the stock.

FAQ

Frequently asked questions about HALO stock

What is the HALO stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Halozyme Therapeutics, Inc. have a median 12-month price target of $105, with estimates ranging from $70 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HALO stock a buy right now?

Of the 9 analysts covering Halozyme Therapeutics, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Halozyme Therapeutics, Inc. 97 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HALO?

As at 5 Oct 2026, Halozyme Therapeutics, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will HALO stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies -4.3% from the last close, and Ticker Nerd's factor model ranks Halozyme Therapeutics, Inc. 97 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HALO stock forecast for 2030?

No analyst covering Halozyme Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HALO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $115 over the next 12 months.

How has HALO stock performed over the past year?

Halozyme Therapeutics, Inc. returned +63.8% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Halozyme Therapeutics, Inc. do?

Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines.

What is the latest news on HALO?

The most recent item we track (PRNewsWire, 6 Oct 2026): "Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology". Halozyme expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE® with two additional exclusive targets. The expansion increases argenx’s exclusive access to ENHANZE® from six targets to eight.

Company

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort. The company also develops, manufactures, and commercializes drug-device combination products with advanced auto-injector technology for use in areas such as oncology and other specialty therapeutic settings. In addition to its platform business, Halozyme Therapeutics Inc. markets proprietary products including Hylenex and XYOSTED, and works with pharmaceutical partners to support a range of commercial and development-stage programs. Headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a specialized role in the biopharmaceutical market by providing technologies that help improve how existing medicines are delivered and used.

CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. · 423 employees · United States · https://halozyme.com